Clinical Trials
24
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (23 trials with phase data)• Click on a phase to view related trials
Magnetic Resonance Imaging (MRI) Guided Stereotactic Adaptive Radiotherapy for Targeting Abdominal Cancer
- Conditions
- Abdominal Cancer
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-07-11
- Lead Sponsor
- Australasian Gastro-Intestinal Trials Group
- Target Recruit Count
- 100
- Registration Number
- NCT06604533
- Locations
- 🇦🇺
GenesisCare - St Vincent's Sydney, Darlinghurst, New South Wales, Australia
🇦🇺Austin Health, Melbourne, Victoria, Australia
Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)
- First Posted Date
- 2024-06-04
- Last Posted Date
- 2025-07-29
- Lead Sponsor
- Australasian Gastro-Intestinal Trials Group
- Target Recruit Count
- 40
- Registration Number
- NCT06441747
- Locations
- 🇦🇺
Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia
🇦🇺Monash Medical Centre, Clayton, New South Wales, Australia
🇦🇺Royal North Shore Hospital, St Leonards, New South Wales, Australia
Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours
- Conditions
- Neuroendocrine Tumors
- Interventions
- Drug: Continuation of somatostatin analoguesDrug: Cessation of somatostatin analogues
- First Posted Date
- 2024-04-03
- Last Posted Date
- 2025-08-14
- Lead Sponsor
- Australasian Gastro-Intestinal Trials Group
- Target Recruit Count
- 78
- Registration Number
- NCT06345079
- Locations
- 🇦🇺
Wollongong Hospital, Wollongong, New South Wales, Australia
🇦🇺The Queen Elizabeth Hospital, Adelaide, South Australia, Australia
🇨🇦BC Cancer Agency, Vancouver Cancer Centre, Vancouver, British Columbia, Canada
A Trial of Palliative Chemotherapy, Radiation and Immune Treatment for Oesophageal Cancer: PALEO Study
- First Posted Date
- 2024-03-04
- Last Posted Date
- 2025-07-23
- Lead Sponsor
- Australasian Gastro-Intestinal Trials Group
- Target Recruit Count
- 54
- Registration Number
- NCT06290505
- Locations
- 🇦🇺
Canberra Hospital, Garran, Australian Capital Territory, Australia
🇦🇺Border Medical Oncology, Albury, New South Wales, Australia
🇦🇺Calvary Mater Newcastle, Newcastle, New South Wales, Australia
NEO-adjuvant Chemo-immunotherapy in Pancreatic Cancer
- Conditions
- Pancreatic Cancer
- Interventions
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Australasian Gastro-Intestinal Trials Group
- Target Recruit Count
- 20
- Registration Number
- NCT06094140
- Locations
- 🇦🇺
GenesisCare North Shore, Sydney, New South Wales, Australia
🇦🇺Wollongong Hospital, Wollongong, New South Wales, Australia
🇦🇺Warringal Private Hospital, Melbourne, Victoria, Australia
- Prev
- 1
- 2
- 3
- 4
- Next
News
Imugene Activates First Australian Site for Phase II Colorectal Cancer Vaccine Trial
Imugene has activated its first Australian site for the Phase II Neo-POLEM trial, expanding recruitment for its PD1-Vaxx immunotherapy in both Australia and the United Kingdom.